ArticleAdvances in pharmacological and pharmaceutical sciences2026
Mechanistic Insights Into House Dust Mites Immunotherapy-Induced Desensitization for Sustained Protection of Allergic Rhinitis in Mice.
Article in Advances in pharmacological and pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic Insights Into House Dust Mites Immunotherapy-Induced Desensitization for Sustained Protection of Allergic Rhinitis in Mice.Advances in pharmacological and pharmaceutical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The worldwide prevalence of allergic rhinitis (AR) is substantial and is considered a global health problem. Allergen immunotherapy (AIT) is the only approach that treats the underlying cause of allergy by inducing a desensitization response to the allergen. In this study, we investigated the effectiveness and the possible desensitization mechanisms of house dust mite (HDM) allergen extract-based IT against mice models of AR. The experimental mice were divided into six groups: normal group, normal group with HDM challenge, AR group, and three AR groups that received HDM-IT at low, moderate, and high doses. The effectiveness of HDM-IT was evaluated based on nose-rubbing and sneezing behavior, IL-4 mRNA expression, eosinophil infiltration into nasal mucosal tissue, serum IgE levels, serum IgG2a levels, and serum IgE/IgG2a ratio. This study discovered that the administration of HDM-IT reduced nose-rubbing and sneezing behavior, decreased IL-4 mRNA expression and eosinophil infiltration into nasal mucosal tissue, decreased serum IgE levels, increased serum IgG2a levels, and decreased serum IgE/IgG2a ratio in AR mice. Thus, HDM-IT effectively promotes a desensitization response to HDM allergens in mouse models of AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.